相关实验视频

Updated: Sep 11, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

LINC01082的m5C修饰通过调节miR-543-TNRC6A轴来抑制骨肉瘤的进展

Yawei Hu¹, Jiawen Wu¹, Huaping Zeng²

¹Department of Spine Surgery, People's Hospital of Longhua, Shenzhen, Guangdong, China.

Translational oncology

|August 16, 2025

概括

这项研究表明,LINC01082在骨髓瘤 (OS) 中是下调的. 通过CRISPR/dCas13b-NSUN2调节其5-甲基细胞素 (m5C) 修饰,可以通过稳定LINC01082.2.抑制OS进展.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
在RNA生物学,RNA生物学.

背景情况:

骨髓瘤 (OS) 是一种患儿骨癌,由于转移,预后不佳.
长非编码RNAs (lncRNAs) 调节癌症,但LINC01082在OS中的作用尚不清楚.

研究的目的:

研究LINC01082在骨髓瘤中的功能和调节.
探索5-甲基细胞素 (m5C) RNA修饰在LINC01082稳定性和OS进展中的作用.

主要方法:

评估了OS细胞和组织中的LINC01082表达和功能.
使用MeRIP-qPCR,RIP和CRISPR/dCas13b-NSUN2进行m5C修饰分析.
研究了RNA诱导沉默复合体 (RISC) 中的LINC01082,miR-543和TNRC6A相互作用.

主要成果:

在OS中,LINC01082表达的下调,与生存率差相关.
NSUN2介导的m5C修改通过YBX1.1.稳定了LINC01082
克里斯普尔/dCas13b-NSUN2向性增加了LINC01082,抑制了OS细胞的增殖和迁移.
LINC01082正调节了TNRC6A,miR-543调节了这种相互作用.

结论:

在OS中确定了LINC01082的新型m5C依赖的调节机制.
通过调节LINC01082.2,通过CRISPR/dCas13b-NSUN2介导的m5C编辑显示了骨髓瘤治疗的潜力.

关键词:

现在我们来看看LINC0108282的情况.在NSUN2中,NSUN2是NSUN2.骨质肉瘤骨质肉瘤是什么瘤抑制可以抑制瘤.m5C 修改的修改

更多相关视频

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...